Translational Windows in Chordoma: A Target Appraisal

Samantha E. Hoffman 1, Sally A. Al Abdulmohsen 1, Saksham Gupta 1, Blake M. Hauser 1, David M. Meredith 2, Ian F. Dunn 3 and Wenya Linda Bi 1*

1 Center for Skull Base and Pituitary Surgery, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, United States, 2 Department of Pathology, Harvard Medical School, Brigham and Women’s Hospital, Boston, MA, United States, 3 Department of Neurosurgery, University of Oklahoma College of Medicine, Oklahoma City, OK, United States

Chordomas are rare tumors that are notoriously refractory to chemotherapy and radiotherapy when radical surgical resection is not achieved or upon recurrence after maximally aggressive treatment. The study of chordomas has been complicated by small patient cohorts and few available model systems due to the rarity of these tumors. Emerging next-generation sequencing technologies have broadened understanding of this disease by implicating novel pathways for possible targeted therapy. Mutations in cell-cycle regulation and chromatin remodeling genes have been identified in chordomas, but their significance remains unknown. Investigation of the immune microenvironment of these tumors suggests that checkpoint protein expression may influence prognosis, and adjuvant immunotherapy may improve patient outcome. Finally, growing evidence supports aberrant growth factor signaling as potential pathogenic mechanisms in chordoma. In this review, we characterize the impact on treatment opportunities offered by the genomic and immunologic landscape of this tumor.

Keywords: chordoma, genomics, immunology, targeted therapy, checkpoint inhibition

INTRODUCTION

Chordomas are locally aggressive tumors arising from fetal notochord remnants with an average annual incidence of 0.088 per 100,000 in the United States (1). These tumors frequently occur at the skull base, followed by sacrum and vertebral bodies, with increasing incidence with age (1). Gross total resection followed by adjuvant radiation offers long-term disease control in many patients (2, 3). However, encasement of vital neurovascular structures and concealed nests of tumor may hinder complete eradication, leading to repeated recurrences following subtotal resection (4, 5). They are also prone to seeding and late metastasis (6). Once recurrent, chordomas are extremely refractory to cure. Chemotherapy has been used for recurrent and metastatic disease, without any consistent efficacy thus far (7, 8).

The difficulties of managing aggressive and refractory chordoma have motivated study of the biological underpinnings of this disease. Genome-scale sequencing approaches and a resurgent interest in tumor immunology have been pivotal in expanding our understanding of chordoma. In this review, we discuss recent advances in the understanding of chordoma biology with a focus on its immune and extracellular microenvironment.

HISTOPATHOLOGIC CHARACTERISTICS

Although the notochord is derived from the ectoderm, chordoma shows both epithelial and mesenchymal differentiation. Their spectrum of inter- and intratumoral histological patterns render their level of differentiation and clinical behavior challenging to predict (9).
Hoffman et al. Translational Windows in Chordoma

The World Health Organization classification of chordoma subtypes includes conventional chordoma (Figure 1), chondroid chordoma (Figure 2), and dedifferentiated chordomas (Figure 3). Conventional chordomas show three neoplastic cell types in a myxoid stroma: (1) intermediate-sized physaliphorous cells are the main proliferating cell type and appear as distinctive vacuolated cells in cords and lobules, (2) large cells with prominent vesicular nuclei, and (3) small cells with pyknotic nuclei. Dedifferentiated chordomas are associated with poorer prognosis compared to conventional and chondroid subtypes, while chondroid chordoma is associated with worse survival than classic chordoma (10). Importantly, chondroid chordoma should be distinguished from chondrosarcoma based on brachyury immunopositivity, as chondrosarcoma has a significantly more indolent growth rate than any chordoma, and therefore may merit different treatment considerations than chordoma itself (11).

GENOMIC ALTERATIONS

Some de novo chordomas harbor chromosomal changes, which are associated with poorer prognoses (12, 13). The most common genomic alterations include large copy number losses in chromosomes 1p, 3, 4, 9, 10, 13, and 14; chromosomal deletions are more common than gains (14). Wide-scale deletions in 1p and 9p specifically have been associated with worse prognosis even after resection and radiation (15). Recurrence is not associated with increased copy number loss or gain compared to primary tumors (16).

Brachyury

Brachyury is a protein whose expression is the diagnostic hallmark of chordoma, regardless of subtype (17). Encoded by the TBXT or T gene on chromosome 6q, brachyury binds palindromic T sites to exert DNA-regulatory effects. Germline duplications of T are associated with familial chordomas, while somatic tandem T duplications have been identified in sporadic chordoma (18). Chordomas with increased brachyury expression are associated with poorer prognosis (18).

A member of the T-box protein family, brachyury is a transcription factor that regulates notochord cell fate determination during development (17). Brachyury is also a mediator of the epithelial-to-mesenchymal transition by downregulating E-cadherin expression, explaining both the heterogeneous histology and the metastatic tendency of chordomas (17).

The ubiquitous brachyury expression in chordoma makes it an attractive therapeutic target; however, its nuclear localization has barred access to targeted inhibitors, setting the stage for immunotherapeutic approaches (19). Targeting brachyury with a recombinant yeast vaccine has been found to activate human T cells in vitro and enhance immune response in phase I trials; brachyury vaccination is now being investigated in a phase II trial as well (Table 1) (20).

Cell Cycle Regulation (CDKN2A, PTEN)

Upregulation of other T-box genes in malignancy is thought to repress cell-cycle regulators like Cyclin-dependent kinase inhibitor 2A (CDKN2A). The CDKN2A gene encodes two tumor suppressor proteins that inhibit progression through the cell cycle; mutations in this gene therefore result in an uncontrolled rate of cell proliferation and differentiation via activation of cyclin-dependent kinases 4 and 6 (CDK4/6). Similarly, the
increase in PD-L1 expression (oncogenesis both through loss of tumor suppression and an identified mutations in those genes, though no activating mutations were identified in chordomas (3)). Preserved CDK4/6 expression may serve as a potential biomarker for future screening.

Many chordomas feature PTEN loss, which may drive oncogenesis both through loss of tumor suppression and an increase in PD-L1 expression (7). To date, no studies have examined existing molecular therapies for chordomas with PTEN loss. Instead, PTEN upregulation has been investigated as a sensitizing factor to improve response to PDGFR and mTOR pathway inhibitors in these tumors (24, 25).

**Chromatin Remodeling**

The pathogenesis of chordoma may involve DNA-level dysregulation that promotes oncogene expression or tumor suppressor silencing. A cardinal regulator of chromatin organization and subsequent regulation of gene expression is the Switch/Sucrose Non-Fermentable (SWI/SNF) protein complex. Mutations of SWI/SNF genes result in a loss of chromatin regulation, facilitating neoplastic development via uncontrolled DNA replication and subsequent cell proliferation.

The SMARCB1 gene is a SWI/SNF component that is thought to serve a tumor suppressor role by regulating the histone methylation activity of the transcription factor EZH2 (26). SMARCB1 loss is the defining marker of poorly differentiated chordomas (PDCs), a highly aggressive subtype distinct from dedifferentiated chordomas that occur most frequently in children and at the skull base. Specifically, PDCs display a loss of nuclear SMARCB1 expression and homozygous deletions of SMARCB1, implicating SWI/SNF aberrations in their rapidly progressive course (21, 27–29).

In other chordoma subtypes where SMARCB1 was downregulated but not lost, upregulation of microRNAs associated with transforming growth factor β signaling (TGF-β) was observed (30). TGF-β signaling may drive chordoma progression and survival through both augmented bone formation (31) and anti-inflammatory effects (32).

Mutations in three other SWI/SNF members—PBRM1, SETD2, ARID1A—have been identified as potential drivers in chordomas (18, 29); however, the relevance of these mutations to chordoma etiology remains to be elucidated.

**IMMUNE MICROENVIRONMENT**

The immune microenvironment offers a therapeutic window for chordomas since there are no reliable molecular markers to predict clinical outcome and drug response in these tumors (Table 2) (45). The tumor microenvironment is often more genetically stable than tumor cells, which can rapidly mutate and acquire drug resistance. A lack of successful treatment options and sparse genetic drivers has driven exploration of immunomodulation strategies such as vaccination with tumor-specific neoantigens, chimeric antigen receptor T-cell (CAR-T cell) engineering, and blocking immune checkpoints.

Though chordomas display an elevated immune infiltration, the immune effectors are likely generating an anti-inflammatory tumor microenvironment (46). For instance, infiltrating macrophages in chordomas are predominantly M2 (anti-inflammatory) macrophages; elevated CD47 expression on chordoma cells also downregulates pro-inflammatory macrophage activity (47).

Cytokine signaling generated by the immune microenvironment may augment the malignant behavior of these tumors. Tumor necrosis factor alpha (TNF-α) is an inflammatory cytokine produced by tumor-associated macrophages that can promote tumor growth and progression. Leukemia inhibitory factor (LIF) is a cytokine in the interleukin-6 family whose functions include regulating proliferation of cancer stem cells, like those often found in chordoma (48). Expression of either TNF-α or LIF in chordoma cell lines promoted cell migration, invasive capabilities, and anchorage-independent growth,

phosphate and tensin homolog (PTEN) gene also encodes for a tumor suppressor protein and regulates cell growth (Figure 5).

Genomic analysis of chordoma samples reveals widespread cell cycle dysregulation (14, 21, 22). Both homozygous and heterozygous copy number losses of CDKN2A have been identified in chordomas (14, 18, 21, 22). Of note, tumors with copy number losses in CDKN2A and PTEN also harbored point mutations in those genes, though no activating mutations were identified (21).

The success of CDK4/6 inhibitors in other malignancies has motivated their application to chordomas. Treatment of a CDKN2A-deleted chordoma cell line in vitro with palbociclib, for example, resulted in significant growth inhibition (23). Preserved CDK4/6 expression may serve as a potential biomarker for future screening.

FIGURE 2 | (A) Chondroid chordoma characteristically contains regions forming hyaline cartilage with tumor cells distributed individually in lacunar spaces that greatly resemble (B) low-grade chondrosarcoma, which classically feature hypercellular hyaline cartilage lobules with a permeative growth pattern. Chondrosarcomas of the skull base in particular have variably prominent myxoid areas (arrow) that resemble chondroid chordoma. (C) Brachyury nuclear positivity confirms the diagnosis of chordoma, while being (D) consistently negative in chondrosarcoma.
Hoffman et al. Translational Windows in Chordoma

FIGURE 3 | (A) Dedifferentiated chordoma contains regions of high-grade sarcoma, frequently juxtaposed with regions of conventional chordoma (B). (C) Brachyury positivity is often negative in the dedifferentiated component (arrow). (D) Poorly differentiated chordoma exhibits higher cellularity than conventional chordoma and occasionally shows rhabdoid morphology. (E) Brachyury is reliably positive, and (F) SMARCB1 (INI-1) loss in tumor cells is characteristic of this entity.

FIGURE 3 | (A) Dedifferentiated chordoma contains regions of high-grade sarcoma, frequently juxtaposed with regions of conventional chordoma (B). (C) Brachyury positivity is often negative in the dedifferentiated component (arrow). (D) Poorly differentiated chordoma exhibits higher cellularity than conventional chordoma and occasionally shows rhabdoid morphology. (E) Brachyury is reliably positive, and (F) SMARCB1 (INI-1) loss in tumor cells is characteristic of this entity.

Demonstrating their pro-tumoral and metastatic potential (49). Exposure of chordomas to TNF-α upregulates not only its own gene expression but also LIF expression, and vice versa; both cytokines are correlated with increased tumor size, implicating these factors in chordoma growth (49, 50).

Immune cell signaling also induces alterations in gene expression in chordoma cells. Epithelial marker expression was downregulated while mesenchymal marker expression was upregulated following exposure to TNF-α, implicating TNF-α in the chordoma epithelial-mesenchymal transition (49). Differential gene expression analysis post-TNF-α exposure demonstrated upregulation of the phosphoinositide 3-kinase (PI3K)/Akt, Ras, and Ras-related protein 1 (Rap1) signaling pathways, implicated in progression of chordomas and other malignancies, respectively (49, 51). Pro-angiogenic and anti-apoptotic pathways were also upregulated with longer TNF-α exposure, which may contribute to the survival and metastatic potential of chordomas (49).

The chordoma microenvironment can impact treatment efficacy by limiting the penetration of pro-inflammatory effectors and altering the expression of putative therapeutic targets. LIF has been shown to inhibit CD8+ T-cell entry while increasing tumor-associated macrophage and regulatory T-cell entry into other tumors, decreasing the efficacy of immune checkpoint blockade (48). The abundance of extracellular matrix associated with chordomas may similarly contribute to lymphocyte distribution. Elevated stroma-tumor ratio was associated with decreased infiltration of effector T-cells and an elevated density of regulatory T cells within the tumor (52). TNF-α-exposed chordoma cells displayed increased programmed death-ligand 1 (PD-L1) but downregulated T expression; brachyury-targeted treatments may be impacted as a result (49, 50). Finally, resistance to cytotoxic chemotherapies also increases in these chordoma cells exposed to LIR and TNF-α (49, 50).

Immune Checkpoint

Immune activation is physiologically downregulated by “immune checkpoints” pathways. Regulatory T cells express immune checkpoint ligands that bind to receptors on activated cytotoxic T-cells, inducing T-cell exhaustion. Immune checkpoint proteins normally inhibit autoimmune responses, but cancer cells can also upregulate these ligands to decrease inflammatory response to the tumor. Pharmacologic blockade of these immune checkpoints, known as checkpoint inhibitor drugs, have proven efficacious immunotherapies in several types of cancer, motivating their trial in chordoma (53).

PD-1/PD-L1

Current immunotherapy trials of chordoma have focused on blockade of PD-L1, the immune checkpoint regulator responsible for suppressing regulatory T cell apoptosis (Figure 4). Whether or not chordomas harbor PD-L1 natively remains in contention, but chordoma cell lines uniformly upregulated PD-L1 expression after interferon-γ treatment (46). PD-L1 expression was also...
TABLE 1 | Active trials for surgical, radiation, and medical therapies for chordoma (extrapolated from ClinicalTrials.gov; December 30, 2019).

| Official study title | Treatment | Phase | # Participants | Sponsor | Projected completion date | Trial registration no. |
|----------------------|-----------|-------|----------------|---------|---------------------------|-----------------------|
| **IMMUNOTHERAPY**    |           |       |                |         |                           |                       |
| Nivolumab with or without stereotactic radiosurgery in treating patients with recurrent, advanced, or metastatic chordoma | Nivolumab, stereotactic radiosurgery | I     | 33             | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | March 2021 | NCT02989636 |
| Nivolumab and Ipilimumab in treating patients with rare tumors | Nivolumab, Ipilimumab | II    | 707            | National Cancer Institute | August 2021 | NCT02834013 |
| Nivolumab and Relatlimab in treating participants with advanced chordoma | Nivolumab, Relatlimab | II    | 20             | UCLA/Jonsson Comprehensive Cancer Center | April 2022 | NCT03623854 |
| Talimogene Laherparepvec, Nivolumab, and Trabectedin for sarcoma (TNT) | Talimogene Laherparepvec, Nivolumab, Trabectedin | II    | 40             | Sarcoma Oncology Research Center, LLC | December 2022 | NCT03888311 |
| **SMALL MOLECULE INHIBITORS** |           |       |                |         |                           |                       |
| Nilotinib with radiation for high risk chordoma | Nilotinib | I     | 29             | Massachusetts General Hospital | December 2019 | NCT01407198 |
| Afatinib in locally advanced and metastatic chordoma | Afatinib | II    | 40             | Leiden University Medical Center, Netherlands | December 2019 | NCT03083678 |
| CDK4/6 inhibition in locally advanced/metastatic chordoma | Palbociclib | II    | 43             | University Hospital Heidelberg, Germany | July 2021 | NCT03110744 |
| Anlotinib Hydrochloride vs. Imatinib Mesylate in locally advanced, unresectable or metastatic chordoma (CSSG-03) | Anlotinib Hydrochloride | II    | 60             | Peking University People's Hospital, China | December 2021 | NCT04042597 |
| A phase II, multicenter study of the EZH2 inhibitor Tazemetostat in adult subjects with INI1-negative tumors or relapsed/refractory synovial sarcoma | Tazemetostat | II    | 250            | Epizyme, Inc. | February 2022 | NCT02601950 |
| **NATURAL HISTORY/OBSERVATIONAL** |           |       |                |         |                           |                       |
| Children and adults with chordoma | Natural history | N/A   | 300            | National Cancer Institute | December 2029 | NCT03910465 |
| Genetic clues to chordoma etiology: a protocol to identify sporadic chordoma patients for studies of cancer-susceptibility genes | Observational | N/A   | 400            | National Cancer Institute | N/A | NCT01200680 |
| **SURGERY, RADIATION, OR CHEMOTHERAPY** |           |       |                |         |                           |                       |
| Pemetrexed for the treatment of chordoma | Pemetrexed | I     | 15             | John Wayne Cancer Institute | May 2023 | NCT03955042 |
| BN brachyury and radiation in chordoma | BN brachyury, radiation | II    | 29             | Bavarian Nordic | January 2021 | NCT03595228 |

(Continued)
### TABLE 1 | Continued

| Official study title | Treatment | Phase | # Participants | Sponsor | Projected completion date | Trial registration no. |
|----------------------|-----------|-------|----------------|---------|--------------------------|------------------------|
| Improvement of local control in skull base, spine and sacral chordomas treated by surgery and proton therapy targeting hypoxic cells revealed by [18F]FAZA PET/CT tracers (PROTONCHORDE01) | 18F FAZA, surgery, proton therapy | II | 64 | Institut Curie, France | September 2022 | NCT02802969 |
| Ion Irradiation of Sacrococcygeal Chordoma (ISAC) | Proton radiation, carbon ion radiation | II | 100 | Heidelberg University | June 2023 | NCT01811394 |
| Trial of Proton vs. Carbon Ion Radiation therapy in patients with chordoma of the skull base | Carbon ion radiation, proton radiation | III | 319 | Heidelberg University | August 2023 | NCT01182779 |
| Proton radiation for chordomas and chondrosarcomas | Proton therapy | N/A | 50 | Abramson Cancer Center of the University of Pennsylvania | December 2019 | NCT01449149 |
| A study of IMRT in primary bone and soft tissue sarcoma (IMRIS) | Intensity modulated radiotherapy | N/A | 200 | University College London, United Kingdom | March 2021 | NCT02520128 |
| Sacral Chordoma: Surgery vs. Definitive Radiation therapy in primary localized disease (SACRO) | Surgery, radiation therapy | N/A | 100 | Italian Sarcoma Group | September 2022 | NCT02986516 |
| Randomized Carbon Ions vs. Standard Radiotherapy for radioresistant tumors (ETOILE) | Carbon ion radiation, X-ray radiotherapy, proton radiation | N/A | 250 | Hospices Civils de Lyon, France | May 2024 | NCT02838602 |

found on tumor-infiltrating macrophages and lymphocytes at the tumor-stroma interface (7). Chordomas with negative PD-L1 expression tended to have more PD-L1 positive tumor-infiltrating lymphocytes (TIL), and the prevalence of these cells correlated with metastatic potential (7).

The putative correlation between PD-L1 expression and malignancy augmented interest in checkpoint blockade in chordomas. Avelumab, an anti-PD-L1 monoclonal antibody, enhanced the immune-mediated killing of chordoma cells in vitro; upregulation of PD-L1 on the chordoma cells further increased their sensitivity to lysis (54). Cancer stem cells, which are resistant to radiation and chemotherapy, were also eliminated at higher rates by avelumab, suggesting that chordoma progression and recurrence may rely on immunologic escape mechanisms (54).

PD-L1 expression in chordomas may be further regulated by microRNAs, small non-coding RNA molecules responsible for post-transcriptional regulation of gene expression. Comparison of chordoma tissue with fetal notochords reveals significant microRNA dysregulation that may precede and augment the tumorigenic effects of PD-L1 upregulation (55). MiR-574-3p, for example, is a microRNA whose expression is negatively correlated with PD-L1 expression (56). Chordomas with low miR-574-3p and high PD-L1 expression were associated with higher muscle invasion, more tumor necrosis, and poorer patient outcomes (55). Elucidating the mechanism underlying this anticorrelation could augment checkpoint blockade implementation in these tumors.

**TIM3/Gal9**

T-cell immunoglobulin and mucin-domain 3 (TIM3) has only recently emerged as a target of interest in chordoma immunotherapy and cancer therapy in general (57–59). First identified on cells of the adaptive immune system, TIM3 is also constitutively expressed on innate immune cells (59–61). TIM3 promotes tumor survival by binding to galectin-9 (Gal9) on tumor cells and inducing T cell exhaustion (Figure 4C). (61). Combining anti-TIM3 and anti-PD-1 regimens may better preclude immunotherapy failure compared to monotherapy,
TABLE 2 Completed clinical trials for targeted therapies in chordoma.

| References | Regimen | Mechanism | Study design | # Pts | SD | MR | PR | CR | PD | Median PFS | PFS6 | Median OS |
|------------|---------|-----------|--------------|-------|----|----|----|----|----|------------|------|-----------|
| (33)       | Imatinib| PDGFR TKI | Retrospective| 48    | 34 | 0  | 0  | 0  | 12 | 9.9 months| 65%  | 30 months |
| (34)       | Imatinib, sorafenib, erlotinib, sunitinib, temsirolimus| PDGFR/VEGFR TKI, EGF TKI, PDGFR/VEGFR TKI, mTOR TKI | Retrospective| 80    | 58 | 0  | 5  | 0  | 10 | 9.4 months| NA   | 4.4 years |
| (35)       | Sunitinib| PDGFR/VEGFR TKI | Phase II| 9     | 4  | 0  | 0  | 0  | 5  | NA         | NA   | NA        |
| (36)       | Sorafenib| PDGFR/VEGFR TKI | Phase II| 27    | 12 | 0  | 1  | 0  | 1  | NA         | 85.30%| NA        |
| (37)       | Lapatinib| EGFR TKI | Phase II| 18    | 15 | 0  | 0  | 0  | 3  | 8 months   | NA   | 25 months |
| (38)       | Imatinib| PDGFR TKI | Phase II| 50    | 21 | 9  | 1  | 0  | 9  | 9.2 months| NA   | 34.9 months |
| (39)       | Dasatinib| SRC TKI | Phase II| 32    | NA | NA | NA | NA | NA | 6.3 months | 54%  | 21.6 months |
| (40)       | Imatinib, everolimus| PDGFR TKI, mTOR TKI | Phase II| 43    | 37 | 0  | 1  | 0  | 4  | 14         | N/A  | 47.1 months |
| (41)       | Linsitinib, erlotinib| IGF-1R TKI, EGFR TKI | Phase I| 95    | 33 | 0  | 5  | 0  | 37 | NA         | NA   | NA        |
| (42)       | Imatinib| PDGFR TKI | Phase I| 7     | NA | NA | NA | NA | NA | 10.2 months| NA   | NA        |
| (43)       | Imatinib, sirolimus| PDGFR TKI, mTOR inhibitor | Phase I| 10    | 7  | 0  | 1  | 0  | 1  | NA         | NA   | NA        |
| (44)       | Nilotinib| PDGFR TKI | Phase I| 23    | NA | NA | NA | NA | NA | 58.15 months| N/A  | 61.5 months |

SD, Stable disease; MR, Minor response; PR, Partial response, CR, Complete response, PD, Progressive disease per RECIST analysis.

SD, Stable disease; MR, Minor response; PR, Partial response, CR, Complete response, PD, Progressive disease per RECIST analysis.

invigorating research into the TIM3/Gal9 pathway as a novel pharmaceutical target (62).

Only one study has investigated TIM3/Gal9 in the setting of chordoma, but its results are consistent with corresponding studies in solid and hematological malignancies (63). In a retrospective analysis of 93 skull base chordomas, the only parameter that independently predicted local recurrence-free survival on both univariate and multivariate analysis was the density of TIM3+ lymphocytes (63). Patients with low TIM3+ TILs in their tumors also had better overall survival compared to patients with high TIM3+ TIL density (63). A putative regulator of the Gal9 native to the chordoma microenvironment has been identified: microRNA 455-5p (miR-455-5p) (63). Tumors that are Gal9+/miR-455-5p-high are associated with longer overall survival than Gal9+/miR-455-5p-low tumors, suggesting an intrinsic downregulation mechanism that could be exploited for future immunotherapy design (63).

GROWTH FACTOR SIGNALING

Growth factor signaling pathways are key modulators of cell growth, proliferation, and survival in normal biology. Aberrant and amplified cascades also play a significant role in tumor pathogenesis. Targeted inhibition of known oncogenic growth factors has driven chordoma clinical trials, and genomic analysis of these tumors has provided several new candidate pathways whose roles remain fully unexplored.

PDGF and EGF Pathways

Amplification of platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) signaling has been shown to increase tumor hyperplasia and survival (Figure 5). Both PDGF.
Tyrosine kinases, such as the epidermal growth factor receptor (EGFR), result in activation of downstream signaling cascades and EGF bind to a receptor tyrosine kinase (PDGFR and EGFR), resulting in activation of downstream signaling cascades that regulate proliferation and differentiation. Tyrosine kinase inhibitors (TKIs) can selectively block PDGFR and EGFR phosphorylation and have revolutionized cancer management.

There is significant burgeoning interest in applying TKIs to chordomas (Tables 1, 2). Numerous clinical trials to date have investigated the use of PDGFR and EGFR TKIs as either monotherapies or in combination with other small molecule inhibitors (Table 1). Complete response was not achieved by RECIST analysis in any of the trials or retrospective analyses, with the majority of patients experiencing either stable or progressive disease.

**PI3K/Akt/mTOR Pathway**

The phosphoinositide 3-kinase (PI3K)/Akt signaling pathway regulates cell cycle progression, cellular proliferation, survival, and cell growth (Figure 5). Activating mutations of this pathway, downstream of PDGF and EGF signaling, are some of the most commonly identified driver mutations in malignancy. For example, mutations in mTOR and the tumor suppressors TSC1 and TSC2, components of the PI3K/Akt cascade, have been associated with the development of tuberous sclerosis complex syndrome (TSC) in children. The dual diagnosis of TSC and chordoma in several children motivated the study of the PI3K/Akt pathway in chordomas (64). TSC-associated chordomas emerge significantly earlier than other pediatric chordomas, and sacral chordomas are associated with a significantly better prognosis when concurrent with TSC (64).

Protein analysis reveals a possible mechanism underlying the TSC-chordoma association. Positive expression of phosphorylated AKT and TSC2 identified across chordoma samples indicates loss of tumor suppression stemming from activation of the PI3K pathway (65). Phosphorylated p70S6kinase expression (p-p70S6K), which lies downstream of TSC2 activation, was also identified; together, these data support the use of mTOR inhibitors to treat chordoma (65).

Analysis of chordoma cell lines not associated with TSC also revealed a correlation between PI3K/AKT pathway upregulation and brachyury expression (66). Cells from skull-base chordomas with high brachyury expression had significant upregulation of PI3K/AKT pathway genes compared to low-brachyury tumors (66). Treatment with PI3K/AKT pathway inhibitors resulted in decreased brachyury expression that corresponded with impaired cell growth (66). These results confirmed that PI3K/AKT pathway activation augmented brachyury expression (66). Importantly, mTOR, TSC2, EGFR, and PDGFR were not among the upregulated genes identified in the high-brachyury tumors (66).

Few clinical trials investigating PI3K/AKT/mTOR inhibition in chordomas exist to date; current trials implement mTOR inhibitors secondary to other small-molecule inhibitors (43). A small number of published case reports found neither rapamycin nor everolimus monotherapy to be efficacious (34, 67), despite prior suggestion of rapamycin-responsiveness in patient-derived cell lines (68). A randomized investigation of these therapies may further clarify their efficacy in chordoma treatment.

**IGF-1 Pathway**

Chordomata’s osseous localization has prompted investigation of bone growth regulation as a possible pathogenic pathway. Interest in insulin-like growth factor 1 (IGF-1), one such growth mediator, in chordomas has been spurred by two features of the IGF family. First, IGF-1 effects strong mitogenic activity in bone, which, if dysregulated, could accelerate chordoma development. The IGF-1/IGF-1R axis is also easily targetable by existing small molecular inhibitors.

Emerging literature supports a relationship between IGF-1/IGF-1R expression and prognosis in chordomas. The majority of chordoma samples studied were positive for both IGF-1 and IGF-1R; the level of IGF-1R staining correlated with tumor volume (69). Phosphorylated-IGF-1R expression was also associated with decreased median progression-free survival (70). Activation of IGF-1R signaling may therefore contribute to chordoma growth or progression, presenting a potential new biomarker and targetable pathway (69, 70). Given that the AKT/mTOR pathway lies downstream of IGF-1/IGF-1R signaling (71) and the success of combined mTOR/IGF-1R inhibition in sarcomas (72), future clinical trials could benefit from looking at a similar combined approach to chordoma management. Clinical trials of IGF-1R inhibitors in chordoma have thus far comprised phase I studies of combined anti-IGF-1R/EGFR inhibition and suggest some efficacy to this approach (41, 73).
EXTRACELLULAR MATRIX

Chordomas produce abundant extracellular matrix. High molecular weight melanoma-associated antigen expression is detected in 62% of chordomas, making them an attractive matrix target (74). Cathepsin K is a cysteine protease that is thought to play a role in osteoclast-mediated bone resorption. Its high expression in the invasion fronts of chordoma, compared to chorda dorsalis and chondrosarcoma controls, incriminates Cathepsin K in chordoma’s infiltrative growth (75). Morphogens, signaling molecules that govern embryological tissue development in the process of morphogenesis, along with extracellular signals that regulate embryonic notochord development may also play key roles in establishing a microenvironment that promotes chordoma pathogenesis (76).

FUTURE DIRECTIONS

Novel therapies for chordoma will need to demonstrate efficacy via clinical trials, but several disease and patient-intrinsic factors complicate the execution of these trials (77, 78). First, durability of long-term disease control with complete surgical removal of tumor and invaded bone followed by radiation remains salient for newly diagnosed chordomas. Clinical trials, therefore, center on recurrent and therapy-resistant chordomas for which effective control proves more challenging. The low incidence of these tumors, especially in the recurrent setting, leads to an even smaller population of eligible patients for accrual into diverse clinical trials, which may underpower the testing of any specific hypothesis. The increased average age of chordoma patients and associated comorbidities may further winnow this population following trial exclusion criteria. Lack of access to clinical trials and physician referral patterns may also impact patient enrollment in clinical trials (78). In general, chordoma remains understudied compared to more prevalent malignancies; efforts by patient advocacy groups like the Chordoma Foundation and research consortiums continue to raise awareness and funding for this rare disease.

Future clinical trials for chordoma will benefit from the adoption of innovative and integrative methods to overcome these obstacles (77, 78). Existing trials, such as the Bayesian design of the glioblastoma AGILE trial, may provide a model for efficient assessment of a large armament of therapy options in a rare disease cohort; optimal assignment of patients to clinical trials requires stratification based on clinical indication and prognostic biomarkers, which have yet to be fully elucidated in chordoma (79, 80).

Finally, increased understanding of the biological crosstalk within chordomas highlight a possible role for combination immunogenic therapy moving forward. The tumor-intrinsic and microenvironmental heterogeneity of chordomas portends risk of emerging resistance to any rationally designed, molecularly targeted therapies, while therapies themselves have been shown to induce genomic alterations in multiple cancers. The promise of immunotherapies, either independently or synergistic with molecularly targeted therapies, presents a particularly promising adaptive strategy for future investigation.

In all, clinical and scientific investigations into chordoma hold promise for the identification of genetic, molecular, and immunomodulatory agents involved in the etiology of this malignancy. The results of these and future studies will continue to combat this rare malignancy.

AUTHOR CONTRIBUTIONS

WB conceived of the paper. DM contributed data. SH, SA, SG, BH, and WB contributed to the initial drafting and data synthesis of the manuscript. All authors contributed to and reviewed the final manuscript.

ACKNOWLEDGMENTS

The authors acknowledge support from the following grants: National Institute of General Medical Sciences T32 GM007753 (BH). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of General Medical Sciences or the National Institutes of Health.

REFERENCES

1. Das P, Soni P, Jones J, Habboub G, Barnholtz-Sloan JS, Recinos PF, et al. Descriptive epidemiology of chordomas in the United States. J Neurooncol. (2020) 148:173–78. doi: 10.1007/s11060-020-03511-x
2. Catton C, O’Sullivan B, Bell R, Laperriere N, Cummings B, Fornasier V, et al. Chordoma: long-term follow-up after radical photon irradiation. Radiother Oncol. (1996) 41:67–72. doi: 10.1016/S0167-8140(96)91805-8
3. Russi MS, Hulou MM, Almefty K, Bi WL, Pravdenkova S, Dunn IF, et al. Pediatric clival chordoma: a curable disease that conforms to collins’ law. Neurosurgery. (2018) 82:652–60. doi: 10.1093/neuros/nyx254
4. Hulen CA, Temple HT, Fox WP, Sama AA, Green BA, Eismont FJ. Oncologic and functional outcome following sacrectomy for sacral chordoma. J Bone Joint Surg Am. (2006) 88:1532–9. doi: 10.2106/00004623-200607000-00014
5. Kayani B, Hanna SA, Sewell MD, Saifuddin A, Molloy S, Briggs TWR. A review of the surgical management of sacral chordoma. Eur J Surg Oncol. (2014) 40:1412–20. doi: 10.1016/j.ejso.2014.04.008
6. Chambers PW Schwinn CP. Chordoma. A clinicopathologic study of metastasis. Am J Clin Pathol. (1979) 72:765–76. doi: 10.1093/ajcp/72.5.765
7. Feng Z, Xiang-Lei L, Hai-Tao W, Zuo-Wei W, Bao-Li H, Hai-Feng Z, et al. Programmed cell death 1 expression in esophageal squamous cell carcinoma and association with clinical characteristics. Indian J Cancer. (2015) 52(Suppl. 3):E176–8. doi: 10.4103/0019-509X.186574
8. Stacchiotti S, Casali PG. Systemic therapy options for unresectable and metastatic chordomas. Curr Oncol Rep. (2011) 13:323–30. doi: 10.1007/s11912-011-0176-x
9. Volpe R, Mazarboua A. A clinicopathologic review of 25 cases of chordoma (a pleomorphic and metastasizing neoplasm). Am J Surg Pathol. (1983) 7:161–70. doi: 10.1097/00000478-198301000-00006
10. Wojno KI, Hruban RH, Garin-Chesa P, Huivos AG. Chondroid chordomas and low-grade chondrosarcomas of the craniospinal axis. An immunohistochemical analysis of 17 cases. Am J Surg Pathol. (1992) 16:1144–52. doi: 10.1097/00000478-199212000-00002
11. Almefty K, Pravdenkova S, Colli BO, Al-Mefty O, Golden, Chordoma M. chondrosarcoma: similar, but quite different, skull base tumors. Cancer. (2007) 110:2457–67. doi: 10.1002/cncr.23073

12. Almefty KK, Pravdenkova S, Sawyer J, Al-Mefty, O. Impact of cytogenetic abnormalities on the management of skull base chordomas. J Neurosurg. (2009) 110:715–24. doi: 10.1093/jn/110.3.586

13. Sandberg AA, Bridge JA. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: chondrosarcoma and other cartilaginous neoplasms. Cancer Genet Cytenogenet. (2003) 143:1–31. doi: 10.1016/S0165-4608(03)00002-5

14. Le LP, Nielsen GP, Rosenberg AE, Thomas D, Batten JM, Deshpande V, et al. Recurrent chromosomal copy number alterations in sporadic chordomas. PLoS ONE. (2011) e18846. doi: 10.1371/journal.pone.0018846

15. Zenasos GA, Fernandez-Miranda JC, Mukherjee D, Chang YF, Panayidou K, Snyderman CH, et al. Proressive validation of a molecular prognosticating panel for chladoma. J Neurosurg. (2018) 130:1528–37. doi: 10.3171/2018.3.JNS172321

16. Schei S, Bruderlein S, Lieim T, Starke H, Hermis J, Schulte M, Moller P. Genome-wide analysis of sixteen chordomas by comparative genomic hybridization and cytogenetics of the first human chordoma cell line, UC-CH1. Genes Chromosomes Cancer. (2001) 32:203–11. doi: 10.1002/gcc.1184

17. Nelson AC, Pillay N, Rosenberg AE, Thomas D, Batten JM, Deshpande V, et al. Recurrent chromosomal copy number alterations in sporadic chordomas. PLoS ONE. (2011) e18846. doi: 10.1371/journal.pone.0018846

18. Tenzer LS, Hnilo JF, et al. An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma. Cancer Res. (2010) 70:1247–59. doi: 10.1158/0008-5472.CAN-09-3882

19. Tarpey PS, Brehiai S, Young MD, Martincorena I, Alexandrov LB, Farnond SJ, et al. The driver landscape of sporadic chordoma. Nat Commun. (2017) 8:890. doi: 10.1038/s41467-017-01026-0

20. Palena C, Fernando RG, Van den Abbeeple AD, Yap JT, Alkurst T, et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. (2009) 27:3154–60. doi: 10.1200/JCO.2008.20.9890

21. Bompas E, Le Cesne A, Tsch Bruneel E, Brellecc L, Laurence V, Collard O, et al. Sarafinb in patients with locally advanced and metastatic chordoma: a phase II trial of the French Sarcoma Group (GFS/GETO). Ann Oncol. (2015) 26:2168–73. doi: 10.1093/annonc/mdv300

22. Scatichotti S, Tamborini E, Lo Vullo S, Bozzi F, Messina A, Morosi C, et al. Phase II study on lapatinib in advanced EGFR-positive chordoma. Ann Oncol. (2013) 24:1931–6. doi: 10.1093/annonc/mdt117

23. Scatichotti S, Longhi A, Ferraresi V, Grignani G, Comandone A, Stupp R, et al. Phase II study of imatinib in advanced chordoma. J Clin Oncol. (2012) 30:914–20. doi: 10.1200/JCO.2011.35.3656

24. Schuette SM, Bolevack J, Choy E, Gnanoo KN, Staddon AP, Chow WA, et al. Phase 2 study of dasatinib in patients with alveolar soft part sarcoma, chondrosarcoma, chordoma, epitheliod sarcoma, or solitary fibrous tumor. Cancer. (2017) 123:90–7. doi: 10.1002/cncr.30379

25. Scatichotti S, Morosi C, Lo Vullo S, Casale A, Palassini E, Frezza MA, et al. Imatinib and erverolimus in patients with progressing advanced chordoma: A phase 2 clinical study. Cancer. (2018) 124:6056–63. doi: 10.1002/cncr.31685

26. Macaulay VM, Middleton MR, Eckhardt SG, Rudin CM, Juergens RA, Geldrich R, et al. Phase I dose-escalation study of lisinistin (OSI-906) and erlotinib in patients with advanced solid tumors. Clin Cancer Res. (2016) 22:2897–907. doi: 10.1158/1078-0432.CCR-15-2218

27. Adenis A, Ray-Coquard I, Italiano A, Chauzit E, Bui-Nguyen B, Blay JY, et al. A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumours. Br J Cancer. (2013) 109:2574–8. doi: 10.1038/bjc.2013.648

28. Scatichotti S, Marrari A, Tamborini E, Palassini E, Virdis, E, et al. Response to imatinib plus sirolimus in advanced chordoma. Ann Oncol. (2009) 20:1886–94. doi: 10.1093/annonc/mdp210

29. Cote GM, Barysaukas CM, DeLaney TF, Schwab J, Raskin K, Lozano-Caldroner S, et al. A Phase 1 Study of Nilotinib Plus Radiation in High-Risk Chordoma. Int J Radiat Oncol Biol Phys. (2018) 102:1496–504. doi: 10.1016/j.ijrobp.2018.07.2013

30. Fritzsche FB, Fellenberg J, Moskovskiy L, Sapi Z, Krenacs T, Machado I, et al. CD47/FOXp3+ ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study. Oncoimmunology. (2015) 4:e990800. doi: 10.4161/2162402X.2014.990800

31. Mathios D, Ruzevick J, Jackson CM, Xu H, Shah SR, Taube M, et al. PD-1, PD-L1, PD-L2 expression in the chordoma microenvironment. J Neurooncol. (2015) 121:251–9. doi: 10.1007/s11060-014-1637-5

32. Dancsoo AR, Gao D, Lee AF, Steigen SE, Blay, YJ, Thomas DM, et al. Targeted associations of markers and macrophage-related immune checkpoint expression in sarcomas. Oncoimmunology. (2020) 9:1747340. doi: 10.2147/162402X.2020.1747340

33. Pascual-García M, Bonfíl-Texeidor E, Planas-Rigol E, Rubio-Perez C, Iurlaro R, Arias A, et al. LIF regulates CXCL9 in tumor-associated macrophages and...
prevents CD8+ T cell tumor-infiltration impairing anti-PD1 therapy, Nat Commun. (2019) 10:2416. doi: 10.1038/s41467-019-10369-9

49. Gullooglu S, Tuyusuz EC, Sahin M, Yaltirik CK, Kuskucu A, Ozkan F, et al. The role of TNF-a in chordoma progression and inflammatory pathways. Cell Oncol. (2019) 42:663–77. doi: 10.1007/s13142-019-0054-y

50. Gulluoglu S, Sahin M, Tuyusuz EC, Yaltirik CK, Kuskucu A, Ozkan F, et al. Leukemia inhibitory factor promotes aggressiveness of chordoma. Oncol Res. (2017) 25:1177–88. doi: 10.3727/096504117X1487349743815

51. Xu G, Liu C, Liang T, Zhang Z, Jiang J, Chen J, et al. Gene expression profile and bioinformatics analysis revealed key molecular characteristics of chordoma—before and after TNF-a treatment. Medicine. (2020) 99:e18790. doi: 10.1097/MD.0000000000018790

52. Zou MX, Zheng BW, Liu FS, Wang XB, Hu JR, Huang W, et al. The relationship between tumor-stroma ratio, the immune microenvironment, and survival in patients with spinal chordoma. Neurosurgery. (2019) 85:E1095–110. doi: 10.1093/neuros/nyz333

53. Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. (2018) 62:29–39. doi: 10.1016/j.intimp.2018.06.001

54. Fujii R, Friedman ER, Richards J, Tsang KY, Heery CR, Schom J, et al. Enhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab. Oncotarget. (2016) 7:33498–511. doi: 10.18632/oncotarget.9256

55. Zhou J, Jiang Y, Zhang H, Chen L, Luo P, Li L, et al. Clinicopathological implications of CD8+/Foxp3+ ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients. Cancer Immunol Immunother. (2018) 67:209–24. doi: 10.1007/s00262-017-2080-1

56. Gullooglu S, Tuyusuz EC, Kuskucu A, Ture U, Atalay B, Sahin F, et al. The potential function of microRNA in chordomas. Gene. (2016) 585:76–83. doi: 10.1016/j.gene.2016.03.032

57. He Y, Cao J, Zhao C, Li X, Zhou C, Hirsch, et al. TIM-3: a promising target for cancer immunotherapy. Onco Targets Ther. (2018) 11:7079–9. doi: 10.2147/OTT.S170385

58. Romero D. PD-1 says goodbye, TIM-3 says hello. Nat Rev Clin Oncol. (2016) 13:202–3. doi: 10.1038/nrclinonc.2016.40

59. Sanchez-Fueyo A, Tian J, Picarella D, Domenig C, Zheng BW, et al. Tim-3 inhibits T helper type 1-mediated auto- and allogeneic responses and promotes immunological tolerance. Nat Immunol. (2003) 4:1093–101. doi: 10.1038/nri8978

60. Sakushi K, Ngiow SF, Sullivan JM, Teng MWL, Kuchuro VK, Smyth J, et al. TIM3+FOXp3+ regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology. (2013) 2:e23849. doi: 10.4161/onci.23849

61. Zhou C, Anderson AC, Schubert A, Xiong H, Imotola J, Khoury SJ, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. (2005) 6:1245–52. doi: 10.1038/nii1271

62. Koyama S, Akbay EA, Li YY, Herter-Sprie GS, Kivlin CM, et al. Expression of cathepsin K in chordoma. A retrospective clinical and immunohistochemical study. J Neurosurg. (2018) 128:1428–37. doi: 10.3171/2016.12.JNS161444

63. Chay WY, Teo M, Sittampalam K, Toh, HC. Effective use of thalidomide in the treatment of recurrent metastatic chordoma. J Clin Oncol. (2011) 29:477–80. doi: 10.1200/JCO.2010.34.2139

64. Picardi-Vitiani L, Runci D, D’Alessandrini QG, Cenci T, Martini M, Bianchi F, et al. Chemotherapy of skull base chordoma tailored on responsiveness of patient-derived tumor samples to rapamycin. Neoplasia. (2013) 15:773–82. doi: 10.1593/neo.13150

65. Schipil S, Freoich LV, Leithner A, Beham A, Quehenberger F, Mokry, et al. Does insulin-like growth factor 1 receptor (IGF-1R) targeting provide new treatment options for chordomas? A retrospective clinical and immunohistochemical study. Histopathology. (2012) 60:999–1003. doi: 10.1111/j.1365-2559.2012.04186.x

66. Sommer J, Itani DM, Homlar KC, Keedy VL, Halpern JL, Holt GE, et al. Methylthiadenosine phosphorylase and activated insulin-like growth factor-1 receptor/insulin receptor: potential therapeutic targets in chordoma. J Pathol. (2010) 220:668–17. doi: 10.1002/path.2679

67. Kurumaseha RT, Duddin K, Billsus C, Debelenko LV, Morton CL, Houghton PJ. The insulin-like growth factor-1 receptor-targeting antibody, CP-75,1871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer res. (2009) 69:7662–71. doi: 10.1158/0008-5472.CAN-09-1693

68. May CD, Landers SM, Bolkhakov S, Ma SY, Ingram DR, Kivlin CM, et al. Co-targeting PI3K, mTOR, and IGFIR with small molecule inhibitors for treating undifferentiated pleomorphic sarcoma. Cancer Biol Ther. (2017) 18:816–26. doi: 10.1089/cbio.2017.1373230

69. Aleskic T, Browning L, Woodward M, Phillips R, Page S, Henderson S, et al. Durable response of spinal chordoma to combined inhibition of IGF-1R and EGFR. Front Oncol. (2016) 6:98. doi: 10.3389/fonc.2016. 00098

70. Migliorini D, Mach N, Aguiar D, Vernet R, Landis BN, Becker M, et al. First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies. Oncoimmunology. (2017) 6:e1338235. doi: 10.1080/2162402X.2017.1338235

71. Haeckel C, Krueger S, Kuester D, Ostertag H, Samii M, Buehlinger F, et al. Expression of cathepsin K in chordoma. Hum Pathol. (2000) 31:834–40. doi: 10.1053/hupa.2000.8448

72. Patel P, Brooks C, Seneviratne C, Hess DA, Seguin CA. Investigating microenvironmental regulation of human chordoma cell behaviour. PLoS ONE. (2014) 9:e115909. doi: 10.1371/journal.pone.0115909

73. Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, et al. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. (2012) 13:e196–204. doi: 10.1016/S1470-2245(11)70406-5

74. Chay WY, Teo M, Sittampalam K, Toh, HC. Effective use of thalidomide in the treatment of recurrent metastatic chordoma. J Clin Oncol. (2011) 29:477–80. doi: 10.1200/JCO.2010.34.2139

75. Chay WY, Teo M, Sittampalam K, Toh, HC. Effective use of thalidomide in the treatment of recurrent metastatic chordoma. J Clin Oncol. (2011) 29:477–80. doi: 10.1200/JCO.2010.34.2139

76. Chay WY, Teo M, Sittampalam K, Toh, HC. Effective use of thalidomide in the treatment of recurrent metastatic chordoma. J Clin Oncol. (2011) 29:477–80. doi: 10.1200/JCO.2010.34.2139

77. Chay WY, Teo M, Sittampalam K, Toh, HC. Effective use of thalidomide in the treatment of recurrent metastatic chordoma. J Clin Oncol. (2011) 29:477–80. doi: 10.1200/JCO.2010.34.2139

78. Chay WY, Teo M, Sittampalam K, Toh, HC. Effective use of thalidomide in the treatment of recurrent metastatic chordoma. J Clin Oncol. (2011) 29:477–80. doi: 10.1200/JCO.2010.34.2139